New York State Medicaid Pharmacy and Therapeutics Committee
Meeting Agenda

The Pharmacy & Therapeutics (P&T) Committee will meet June 15, 2012, from 8:45 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

Agenda Items

A. Preferred Drug Program: Initial Review

Description: The Committee will review the following therapeutic classes for Preferred Drug Program inclusion and recommend preferred and non-preferred status.

1. Alpha Reductase Inhibitors (for BPH)
   Drugs Affected: Avodart (dutasteride), finasteride, Jalyn (dutasteride/tamsulosin), Proscar (finasteride)

2. Anabolic Steroids – topical
   Drugs Affected: Androderm (testosterone), Androgel (testosterone), Axiron (testosterone), Fortesta (testosterone), Testim (testosterone)

3. Ophthalmic Antibiotics
   Drugs Affected: Azasite (arthritisomycin), bacitracin, bacitracin/polymyxin B, Bleph-10 (sulfacetamide), erythromycin, Garamycin (gentamicin), gentamicin, Ilopect (erythromycin), Natacyc (natamycin), Neocidin/Neosporin (neomycin/polymyxin/gramicidin), neomycin/bacitracin/polymyxin, neomycin/polymyxin/gramicidin, Neosporin (neomycin/polymyxin/bacitracin), polymyxin/trimethoprim, Polytrim (polymyxin b/trimethoprim), sulfacetamide, tobramycin, Tobrex (tobramycin)

4. Ophthalmic Antibiotic/Steroid Combinations
   Drugs Affected: Blephamide/Blephamide S.O.P (prednisolone acetate/sulfacetamide sodium), Maxitrol (dexamethasone/neomycin sulfate/polymyxin b sulfate), neomycin/bacitracin/polymyxin/hydrocortisone, neomycin/polymyxin/hydrocortisone, neomycin/polymyxin/ dexamethasone, Pred-G/Pred-G SOP (gentamicin/prednisolone), sulfacetamide/prednisolone, Tobradex/Tobradex ST (tobramycin/ dexamethasone), tobramycin/dexamethasone, Zylet (loteprednol etabonate/tobramycin)

B. Preferred Drug Program: Re-review

Description: The Committee will re-review therapeutic classes subject to the Preferred Drug Program periodically as described and listed below. The following therapeutic classes to be re-reviewed contain new relevant clinical and/or financial information. Therapeutic classes not included on this agenda may be re-reviewed at a later date pending new relevant clinical information.
The Committee will review new clinical and financial information as required, to recommend preferred and non-preferred drugs.

The Committee will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information.

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, and unpublished data is poor quality evidence for the purpose of re-review and submission is discouraged.

Those wishing to submit new clinical information must do so in an electronic format by May 31, 2012 or the Committee may not have ample time to review the information.

^The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

1. **Long Acting Opioids**
   (previous review date: June 16, 2011)
   Drugs Affected: Avinza (morphine sulfate ER), Butrans (buprenorphine), Conzip (tramadol ER), Duragesic (fentanyl patch), Exalgo (hydromorphone HCL ER), fentanyl patch, Kadian (morphine sulfate SR), morphine sulfate SR/ER, MS Contin (morphine sulfate CR), Nucynta ER (tapentadol ER), Opana ER (oxymorphone ER), Oramorph SR (morphine sulfate SR), oxycodone HCL CR, Oxycontin (oxycodone HCL CR), oxymorphone ER, Ryzolt (tramadol ER), tramadol ER, Ultram ER (tramadol ER)

2. **Short Acting Opioids**
   (previous review date: June 16, 2011)
   Drugs Affected: APAP/codeine, butalbital/APAP/codeine, butalbital compound with codeine, butorphanol NS, codeine, Cocet/Cocet Plus (APAP/codeine), Demerol (meperidine), Dilaudid (hydromorphone), dihydrocodeine/APAP/caffeine, Endocet (oxycodone/APAP), Endodan (oxycodone/ASA), Fioricet with codeine (butalbital/APAP/codeine/caffeine), Fiorinal with codeine (butalbital/ASA/codeine/caffeine), Hycet (hydrocodone/APAP), hydrocodone/APAP, hydrocodone/ibuprofen, hydromorphone, Ibudone (hydrocodone/ibuprofen), levorphanol, Lorcet/Lorcet Plus (hydrocodone/APAP), Lortab (hydrocodone/APAP), Magnacet (oxycodone/APAP), Margesic H (hydrocodone/APAP), Maxidone (hydrocodone/APAP), meperidine, morphine IR, Norco (hydrocodone/APAP), Nucynta (tapentadol), Opana (oxymorphone), Oxecta (oxycodone), Panlor SS (dihydrocodeine/APAP/caffeine), oxycodone, oxycodone/APAP, oxycodone/ASA, oxycodone/ibuprofen, OxIR (oxycodone), oxymorphone, pentazocine/APAP, pentazocine/naloxone, Percocet (oxycodone/APAP), Percodan (oxycodone/ASA), Primalev (oxycodone/APAP), Reprexain (hydrocodone/ibuprofen), Roxicet (oxycodone/APAP), Roxicodone (oxycodone), Rybix ODT (tramadol), Synalgos DC (dihydrocodeine/APAP/caffeine), tramadol, tramadol/APAP, Trezix (dihydrocodeine/APAP/caffeine), Tylenol #3 (APAP/codeine), Tylenol #4 (APAP/codeine), Tylox (oxycodone/APAP), Ultracet (tramadol/APAP), Ultram (tramadol), Vicoprofen (hydrocodone/ibuprofen), Xolox (oxycodone/APAP), Xodol (hydrocodone/APAP), Zydone (hydrocodone/APAP), Vicodin/Vicodin ES/Vicodin HP (hydrocodone/APAP), Zamicet (hydrocodone/APAP)
3. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors  
(previous review date: June 16, 2011)  
Drugs Affected: Janumet (sitagliptin/metformin HCL), Janumet XR (sitagliptin/metformin HCL), Januvia (sitagliptin), Jentadueto (linagliptin/metformin), Juvisync (sitagliptin/simvastatin), Kombiglyze XR (saxagliptin/metformin ER), Onglyza (saxagliptin), Tradjenta (linagliptin)

4. Glucagon-like-Peptide-1 (GLP-1) Agents  
(previous review date: June 16, 2011)  
Drugs Affected: Byetta (exenatide), Bydureon (exenatide ER), Victoza (liraglutide)

5. Pancreatic Enzymes  
(previous review date: June 16, 2011)  
Drugs Affected: Creon (amylase/lipase/protease), Pancreaze (amylase/lipase/protease), pancrelipase (amylase/lipase/protease), Zenpep (amylase/lipase/protease)

6. Anti-Emetics  
(previous review date: June 16, 2011)  
Drugs Affected: Anzemet (dolasetron), granisetron, ondansetron, Sancuso (granisetron patch), Zofran (ondansetron), Zuplenz (ondansetron)

7. Sulfasalazine Derivatives  
(previous review date: June 16, 2011)  
Drugs Affected: Asacol/Asacol HD (mesalamine), Apriso (mesalamine), Azulfidine (sulfasalazine), Azulfidine Entab (sulfasalazine DR/EC), balsalazide, Colazal (balsalazide), Dipentum (olsalazine), Lialda (mesalamine), Pentasa (mesalamine), sulfasalazine IR, sulfasalazine DR/EC

8. Immunomodulators – injectable  
(previous review date: April 29, 2010)  
Drugs Affected: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), Kineret (anakinra), Orencia (abatacept), Simponi (golimumab)

9. Phosphate Binders/Regulators  
(previous review date: April 29, 2010)  
Drugs Affected: calcium acetate, Eliphos (calcium acetate), Fosrenol (lanthanum carbonate), Phoslo (calcium acetate), Phoslyra (calcium acetate), Renagel (sevelamer HCL), Renvela (sevelamer carbonate)

10. Urinary Tract Antispasmodics  
(previous review date: April 15, 2011)  
Drugs Affected: Detrol (tolterodine), Detrol LA (tolterodine LA), Ditropan (oxybutynin), Ditropan XL (oxybutynin XL), Enablex (darifenacin), Gelique (oxybutynin gel), oxybutynin, oxybutynin ER, Oxytrol (oxybutynin), Sanctura (trospium), Sanctura XR (trospium), Toviaz (fesoterodine fumarate), trospium, Vesicare (solifenacin)

11. Antivirals – oral  
(previous review date: September 16, 2010)
Drugs Affected: acyclovir, famciclovir, Famvir (famciclovir), valacyclovir, Valtrex (valacyclovir), Zovirax (acyclovir)

12. Beta Blockers  
(previous review date: March 11, 2010)  
Drugs Affected: acebutolol, atenolol, betaxolol, bisoprolol fumarate, bisoprolol fumarate/HCTZ, Bystolic (nebivolol), carvedilol, Coreg (carvedilol), Coreg CR (carvedilol CR), Corgard (nadolol), Corzide (nadolol/bendroflumethiazide), Dutoprol (metoprolol succinate/HCTZ), Inderal LA (propranolol LA), Innopran XL (propranolol XL), Kerlone (betaxolol), labetalol, Levatol (penbutolol), Lopressor (metoprolol tartrate), Lopressor HCT (metoprolol tartrate/HCTZ), metoprolol tartrate/HCTZ, metoprolol succinate XL, metoprolol tartrate, nadolol, nadolol/bendroflumethiazide, pindolol, propranolol, propranolol/HCTZ, propranolol SA, Sectral (acebutolol), Tenoretic (atenolol/chlorthalidone), Tenormin (atenolol), timolol maleate, Toprol XL (metoprolol succinate XL), Trandate (labetalol), Zebeta (bisoprolol fumarate), atenolol/chlorthalidone, Ziac (bisoprolol fumarate/HCTZ)

13. Cholesterol Absorption Inhibitors  
(previous review date: April 30, 2008)  
Drugs Affected: cholestyramine, cholestyramine light, Colestid (colestipol), colestipol, Prevalite (cholestyramine), Questran (cholestyramine), Questran Light (cholestyramine), Welchol (colesevelam), Zetia (ezetimibe)

14. Fluoroquinolones – oral  
(previous review date: April 29, 2010)  
Drugs Affected: Avelox (moxifloxacin), ciprofloxacin, ciprofloxacin ER, Cipro (ciprofloxacin), Cipro XR (ciprofloxacin ER), Factive (gemifloxacin), Levaquin (levofloxacin), levofloxacin, Noroxin (norfloxacin), ofloxacin, Proquin XR (ciprofloxacin)

15. Ophthalmic Prostaglandin Agonists  
(previous review date: April 15, 2011)  
Drugs Affected: latanoprost, Lumigan (bimatoprost), Travatan Z (travoprost), Xalatan (latanoprost), Zioptan (tafluprost)

16. Ophthalmic Antihistamines  
(previous review date: April 15, 2011)  
Drugs Affected: azelastine, Bepreve (bepotastine), Elestat (epinastine), Emadine (emedastine), epinastine, Lastacaft (alcaftadine), Optivar (azelastine), Patanol (olopatadine), Pataday (olopatanide)

17. Topical Steroids – medium potency  
(previous review date: June 15, 2011)  
Drugs Affected: Cloderm (clocortolone), Cordran (flurandrenolide), Cutivate (fluticasone), Dermatop (prednicarbate), Elocon (mometasone), flucinolone, fluticasone, hydrocortisone butyrate, hydrocortisone valerate, Luxiq (betamethasone), mometasone, Pandel (hydrocortisone), prednicarbate

18. Topical Steroids – very high potency  
(previous review date: June 15, 2011)  
Drugs Affected: clobetasol, Clobex (clobetasol), Cormax (clobetasol), halobetasol, Olux, Olux-E (clobetasol), Temovate/Temovate-E (clobetasol), Ultravate (halobetasol)
Agenda Timeline (subject to change based on meeting proceedings)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 - 9:00</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td>9:00 - 10:30</td>
<td>Public Comment Period</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>Break</td>
</tr>
<tr>
<td>10:45 - 12:00</td>
<td>PDP Clinical Reviews</td>
</tr>
<tr>
<td>12:00 - 1:30</td>
<td>Lunch Break/Executive Session (PDP financial review)</td>
</tr>
<tr>
<td>1:30 - 1:45</td>
<td>Summary of P&amp;T Committee Recommendations</td>
</tr>
<tr>
<td>1:45 - 3:00</td>
<td>PDP Clinical Reviews</td>
</tr>
<tr>
<td>3:00 - 3:30</td>
<td>Afternoon Break/Executive Session (PDP financial review)</td>
</tr>
<tr>
<td>3:30 - 3:45</td>
<td>Summary of P&amp;T Committee Recommendations</td>
</tr>
<tr>
<td>3:45 - 4:30</td>
<td>Updates, Comments and Adjournment</td>
</tr>
</tbody>
</table>

- Interested parties must notify the Department of Health (DoH) by **June 7, 2012** of their request to address the P&T Committee during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing pandtc@health.state.ny.us. (Please reference P&T Committee).

- Public comments are limited to therapeutic classes on the agenda and new clinical information for the PDP classes being re-reviewed. Comments must be brief (two minutes) and the total comment period will not exceed ninety (90) minutes. DoH reserves the right to limit the number of interested parties providing public comment in order to meet timelines and accomplish meeting objectives.

- All written statements must be received in an electronic format by **June 7, 2012**. Written statements should summarize key points and may not exceed two (2) pages in length.

- Clinical information must be submitted in an electronic format by **May 31, 2012**, or the Committee may not have ample time to review the information. For the therapeutic classes subject to the PDP re-review, submitted clinical information must be new since the previous review of the therapeutic class. Any studies cited should be referenced, with the primary source of funding included.

- Any information regarding the P&T Committee meeting must be sent to the DoH to ensure distribution to all Committee members. Interested parties should not contact or send any information directly to Committee members.

Posted 5/15/2012